Alzheimer's disease: cardiovascular risk factors must be assessed

被引:6
作者
Antoine, V
Rigaud, AS
机构
[1] CHI Poissy Maisonnees, Consultat Memoire, F-78300 Poissy, France
[2] Hop Broca, Serv Geriatrie, F-75013 Paris, France
来源
REVUE DE MEDECINE INTERNE | 2006年 / 27卷 / 01期
关键词
elderly; Alzheimer's disease; vascular dementia; vascular risk factors;
D O I
10.1016/j.revmed.2005.04.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. - Dementia is nowadays of major importance in public health. Alzheimer's disease and vascular cognitive impairments are its main aetiology in the elderly. The cause of Alzheimer's disease remains unknown. The factor initiating the physiopathology of this neurodegenerative disease is source of controversy. Current knowledge and key points. - The theory of a neurotoxicity initiated by amyloid deposition is questioned. A growing number of data suggest a central role of cardiovascular risk factors and alteration of arterial walls, inducing chronic brain hypoperfusion, as the primary trigger in the physiopathology of the disease. These data are based on epidemiological, physiopathological, neuroimaging, neuropathological and pharmacological studies. However, the exact link between arteriosclerosis, vascular cognitive impairment and Alzheimer's disease remains controversial. Future prospects and projects. - These debates point out the crucial importance of the assessment of cardiovascular risk factors, as a preventable cause, either of cognitive decline, morbidity and mortality. In this aim, major targets could be different when primary or secondary prevention are at stake. These controversies also suggest new research directions towards Alzheimer's disease physiopathology, and for pharmacological interventions aimed on the prevention of cognitive decline or the curative treatment for this disease. (C) 2005 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:21 / 31
页数:11
相关论文
共 120 条
[1]  
Alexopoulos GS, 1997, AM J PSYCHIAT, V154, P562
[2]  
[Anonymous], 2003, COCHRANE DB SYST REV
[3]   MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial [J].
Aronow, WS .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (05) :717-718
[4]   Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation [J].
Barber, M ;
Tait, RC ;
Scott, J ;
Rumley, A ;
Lowe, GDO ;
Stott, DJ .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) :1873-1878
[5]  
Bellelli G, 2000, BRIT MED J, V321, P1157
[6]  
Boddaert J, 2003, PRESSE MED, V32, P1707
[7]   Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease [J].
Borroni, B ;
Pettenati, C ;
Bordonali, T ;
Akkawi, N ;
Di Luca, M ;
Padovani, A .
NEUROSCIENCE LETTERS, 2003, 343 (03) :213-215
[8]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[9]   Results of the pilot study for the Hypertension in the Very Elderly Trial [J].
Bulpitt, CJ ;
Beckett, NS ;
Cooke, J ;
Dumitrascu, DL ;
Gil-Extremera, B ;
Nachev, C ;
Nunes, M ;
Peters, R ;
Staessen, JA ;
Thijs, L .
JOURNAL OF HYPERTENSION, 2003, 21 (12) :2409-2417
[10]   Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins [J].
Casserly, I ;
Topol, E .
LANCET, 2004, 363 (9415) :1139-1146